Lp(a): How to Interpret Your Result

What Is Lp(a) and Why Does It Matter?

Lp(a) is a lipoprotein particle made of an LDL-like core bound to a protein called apolipoprotein(a). Your liver produces it. The amount your body makes is controlled almost entirely by the LPA gene, which means your Lp(a) level is fixed from birth and stays relatively stable throughout life [1]. This makes it unlike LDL cholesterol, triglycerides, or HDL, all of which respond to food choices, medications, and body weight.

The particle promotes atherosclerosis through three distinct pathways: it deposits cholesterol in artery walls the same way LDL does, it carries oxidized phospholipids that trigger vascular inflammation, and it interferes with fibrinolysis (the body's clot-dissolving system) because apolipoprotein(a) structurally resembles plasminogen [2]. A 2018 Mendelian randomization study published in JAMA Cardiology (Burgess et al., N=393,751) found that each 50 nmol/L increase in genetically predicted Lp(a) was associated with a 9% higher risk of coronary heart disease and a 10% higher risk of aortic valve stenosis [3]. That link is causal, not merely correlational.

The 2019 ESC/EAS dyslipidemia guidelines state: "Lp(a) measurement should be considered at least once in each adult's lifetime to identify those with very high inherited Lp(a) levels above 180 mg/dL (approximately 430 nmol/L) who may have a lifetime risk of atherosclerotic cardiovascular disease equivalent to heterozygous familial hypercholesterolaemia" [4]. The EAS reinforced this position in a 2022 consensus statement, broadening the recommendation to anyone with a family history of premature cardiovascular disease [5].

Who Should Get an Lp(a) Test?

Every adult should be tested at least once. The 2022 European Atherosclerosis Society consensus panel recommends universal Lp(a) screening, calling it a "once-in-a-lifetime measurement" that permanently classifies cardiovascular risk [5]. The Canadian Cardiovascular Society adopted similar guidance in 2021 [6]. In the United States, the National Lipid Association (NLA) recommends Lp(a) testing for patients with a personal or family history of premature atherosclerotic cardiovascular disease, familial hypercholesterolemia, recurrent cardiovascular events despite statin therapy, or a 10-year ASCVD risk of 5% or higher [1].

Some situations make testing particularly urgent. If a first-degree relative had a heart attack before age 55 (men) or 65 (women), your odds of carrying high Lp(a) are meaningfully above average. Patients with aortic stenosis of unclear origin should also be checked, because Lp(a) is an independent driver of valve calcification [3]. And if your LDL is well-controlled on a statin yet residual risk remains, Lp(a) may explain the gap.

You do not need to fast before an Lp(a) blood draw. The level does not fluctuate with meals, exercise, or time of day [7].

How to Read Your Lp(a) Result: Units and Cutoffs

This is where confusion starts. Two different units exist.

nmol/L is the preferred reporting unit. It directly measures the number of Lp(a) particles regardless of their size. The EAS, NLA, and most lipid specialists consider nmol/L the standard [5].

mg/dL measures the mass of Lp(a) and is still used by some U.S. labs. The problem: because apolipoprotein(a) comes in multiple isoform sizes (coded by Kringle IV type 2 repeats), a simple conversion factor does not exist. A commonly cited rough estimate is to multiply mg/dL by approximately 2.0 to 2.5 to get nmol/L, but this is imprecise and can misclassify patients at the borderline [8].

Here is a practical interpretation framework:

| nmol/L | Approximate mg/dL | Interpretation | |---|---|---| | <30 | <14 | Desirable. Low added CV risk from Lp(a). | | 30 to 50 | 14 to 30 | Borderline. Consider other risk factors for context. | | 50 to 125 | 30 to 50 | Elevated. Independent risk factor; intensify LDL lowering. | | >125 | >50 | High. Treat as a major risk enhancer. Specialist referral if needed. | | >430 | >180 | Very high. Lifetime ASCVD risk may approach that of familial hypercholesterolemia [4]. |

If your lab report only shows mg/dL, ask your provider whether the assay is isoform-insensitive. Isoform-sensitive assays (reported in nmol/L) give more accurate risk stratification. Dr. Florian Kronenberg, lead author of the 2022 EAS consensus statement, has noted: "Reporting Lp(a) in nmol/L using an isoform-insensitive assay is the current best practice, and mass-based units should be phased out" [5].

What Elevated Lp(a) Means for Your Cardiovascular Risk

A result above 50 nmol/L means Lp(a) is an independent contributor to your atherosclerotic risk. The Copenhagen General Population Study (N=46,200) showed that participants with Lp(a) above 50 mg/dL (approximately 120 nmol/L) had a 1.5-fold higher risk of myocardial infarction and a 1.6-fold higher risk of aortic valve stenosis compared to those with Lp(a) below 10 mg/dL [9]. These associations held after adjusting for LDL-C, HDL-C, triglycerides, diabetes, hypertension, smoking, and BMI.

The risk is continuous. There is no single "safe" threshold. Higher Lp(a) means proportionally greater risk, with the steepest part of the curve above 150 nmol/L [2]. For context, roughly 20% of the global population has Lp(a) above 50 nmol/L, and about 5% exceeds 125 nmol/L [5].

What elevated Lp(a) does not mean: it does not mean you will have a heart attack. It means one of your risk inputs is permanently higher than average, and that information should shape how aggressively you and your clinician manage everything else: LDL targets, blood pressure, metabolic health, and lifestyle factors you can control.

The 2019 ESC/EAS guidelines recommend that patients with very high Lp(a) (>430 nmol/L) be treated with the same urgency as those with heterozygous familial hypercholesterolemia, including consideration of PCSK9 inhibitor therapy to drive LDL-C as low as possible [4].

What a Low Lp(a) Result Means

A result below 30 nmol/L is desirable. It means Lp(a) is not adding meaningfully to your baseline cardiovascular risk. Around 35% to 40% of people of European ancestry fall in this range [10].

Low Lp(a) does not protect against heart disease from other causes. You can still have dangerously high LDL, uncontrolled hypertension, or insulin resistance. Think of Lp(a) as one dial among many. A low reading simply takes this particular dial off the dashboard as a concern.

People of African descent tend to have higher median Lp(a) levels than those of European or East Asian ancestry. This is a population-level observation driven by LPA gene variant frequencies, not a reflection of lifestyle or diet [10]. The risk thresholds (50 nmol/L, 125 nmol/L) apply equally across ethnic groups based on current evidence [5].

Can You Lower Lp(a)?

This is the hardest part of the Lp(a) conversation. Short answer: not easily, and not yet with a targeted FDA-approved drug.

What does not work. Statins do not lower Lp(a). Some data suggest statins raise Lp(a) by 10% to 20%, though the clinical significance of this increase is debated [11]. Diet, exercise, and weight loss have minimal effect on Lp(a) because production is genetically fixed [1]. Fibrates, ezetimibe, and fish oil also fail to move Lp(a) in any clinically meaningful way.

What modestly works. Niacin (extended-release, 1,500 to 2 to 000 mg daily) lowers Lp(a) by approximately 20% to 30%, but the AIM-HIGH trial (N=3,414) and HPS2-THRIVE trial (N=25,673) showed no cardiovascular outcome benefit from adding niacin to statin therapy, and side effects were significant [12]. PCSK9 inhibitors (evolocumab, alirocumab) lower Lp(a) by roughly 20% to 30% as a secondary effect. A post-hoc analysis of the FOURIER trial (N=27,564) found that patients with higher baseline Lp(a) derived greater absolute benefit from evolocumab, and that each 25 nmol/L reduction in Lp(a) was associated with a 2.4% relative reduction in coronary events [13].

What is coming. Two RNA-targeted therapies are in phase 3 trials and represent the first drugs designed specifically to lower Lp(a):

• Pelacarsen (Novartis). An antisense oligonucleotide that reduced Lp(a) by up to 80% in the phase 2 trial (N=286) [14]. The phase 3 HORIZON trial (NCT04023552, N=8,323) is evaluating cardiovascular outcomes and results are expected in 2026 [15].
• Olpasiran (Amgen). A small interfering RNA that reduced Lp(a) by up to 101% in the phase 2 OCEAN(a)-DOSE trial (N=281) [16]. The phase 3 OCEAN(a) Outcomes trial is underway.

Until these results read out, the clinical strategy for high Lp(a) patients is indirect: push LDL-C lower than standard targets, control blood pressure tightly, optimize metabolic health, and consider aspirin in select cases after discussing bleeding risk [5].

Lp(a) in Context: How It Fits with Your Other Lipid Numbers

Your standard lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) does not capture Lp(a). It must be ordered separately. And because Lp(a) particles contain cholesterol, they contribute to your measured LDL-C value. In patients with very high Lp(a), up to 30% to 45% of what the lab reports as "LDL cholesterol" may actually be cholesterol carried on Lp(a) particles rather than true LDL particles [1].

This has a practical consequence. If your LDL-C is 130 mg/dL and your Lp(a) is 200 nmol/L, your corrected LDL-C (subtracting the Lp(a)-cholesterol contribution) may be closer to 100 mg/dL. Some lipid specialists calculate "Lp(a)-corrected LDL-C" to get a more accurate picture. The formula commonly used is: corrected LDL-C = measured LDL-C minus [Lp(a) in mg/dL × 0.30] [8]. Not every lab does this automatically.

ApoB is another marker worth pairing with Lp(a). ApoB counts all atherogenic particles (LDL, VLDL, Lp(a)) in a single number. A high ApoB with high Lp(a) suggests an especially heavy atherogenic burden [4].

When to Retest Lp(a)

For most people: never. One measurement classifies your genetic baseline. Lp(a) does not change with diet, exercise, age, or most medications [5].

Exceptions exist. Retest if your first result was borderline (40 to 60 nmol/L) and the clinical decision depends on the exact number. Retest if you start a PCSK9 inhibitor and want to quantify the Lp(a) reduction. Retest if you enroll in a trial of pelacarsen or olpasiran. And retest if kidney function declines significantly, because nephrotic syndrome and end-stage renal disease can raise Lp(a) [7].

Thyroid status also affects Lp(a). Hypothyroidism raises it; treating with levothyroxine can bring it back toward your genetic baseline [7]. If you were hypothyroid at the time of your first test and have since been treated, a repeat draw is reasonable.

Women may see Lp(a) rise 20% to 50% after menopause due to declining estrogen [17]. Oral estrogen (not transdermal) lowers Lp(a) by roughly 20% to 25%, one of the few interventions with a measurable effect [17]. This does not mean estrogen is prescribed for Lp(a) lowering, but it is a relevant consideration in postmenopausal women already weighing hormone therapy for other reasons.

The single most useful thing you can do after receiving an elevated Lp(a) result is to ensure your LDL-C is below the 2019 ESC/EAS recommended target for your risk category, because Lp(a) and LDL-C act synergistically on plaque formation [4].